Navigation Links
DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
Date:1/29/2009

EVRY, France, January 29 /PRNewswire/ -- DNA Therapeutics, an emerging biopharmaceutical company specialized in the development of innovat0ive medicines in oncology, announces the successful closing of its Series A equity investment round. The investor syndicate led by SGAM SEFTI with two of the previous seed investors, Blue Medical Investments and G1J-Ile de France, is committed to invest 2.2 million EUR based on certain milestones to be met. Since June 2008, DNA Therapeutics has raised 3 million EUR (US$4 million) through the current Series A and the previous seed financing round led by Inserm-Transfert Initiative.

The funds will enable DNA Therapeutics to advance the vectorization and the additional proofs of concept, and to achieve regulatory preclinical studies of its lead product, named Dbait. DNA Therapeutics is developing a new class of drugs fighting tumor resistance to conventional therapies. In current cancer treatment, the effectiveness of radiotherapy and chemotherapy are often limited by the action of DNA repair processes on the damages caused by these therapies. The innovative aspect of siDNA (signal interfering DNA) technology developed in DNA Therapeutics is to use a short fragment of DNA, a mimetic of DNA damage, to interfere with the sensing and signaling of DNA damages in the nucleus, and ultimately, inhibit their repair during the treatment period. Thus siDNA increases the effectiveness of radiotherapy and chemotherapy without adding any cytotoxic effect. The company possesses a portfolio of exclusive worldwide licenses resulting from the pioneering work of its founding scientists at the Institut Curie, the CNRS, the INSERM (French NIH) and the French National Museum of Natural History.

Prof. Jian-Sheng Sun, co-founder, Chairman and CEO commented: "We are delighted to have received this significant investment from SGAM SEFTI that is strongly committed to support Life Science innovation at early stage in France and in Europe, and that shares our business vision and values the potential of our drug development based on our unique proprietary siDNA technology. This financing will allow DNA Therapeutics to move ahead with an aggressive timeline for the preclinical development of Dbait which will enter into phase I/II clinical trial by the end of 2010."

"Since January 2006, we have been carrying out fundamental work consisting of creating and shaping our company portfolio to meet SEFTI's objectives. This effort has resulted in an original portfolio companies, mainly in France and Switzerland, close to clinical stage, and attractive to big biotech, pharmaceutical and medical device companies. Adding DNA Therapeutics, which develops a breakthrough treatment in oncology, to SEFTI's portfolio companies, is in line with our innovative investment strategy. Today, SGAM SEFTI has already invested, or is ready to invest in near term, more than half of the fund's commitments," said Beatrice Denys, manager of the fund. "The life of the fund is entering a second phase in which one of our priorities will be to endeavor to demonstrate the validity of our investment choices, notably through the emphasis placed on organizing output," added Eric Viaud, exclusive advisor of SEFTI.

About DNA Therapeutics

DNA Therapeutics SA (http://www.dna-therapeutics.com) headquartered in the Genopole biocluster (Evry, France) was founded in June 2006. Its original siDNA technology consists in interfering with DNA repair pathways that cancer cells use to resist radiotherapy and chemotherapy. Its lead product, Dbait, will be first administered locally in combination with radiotherapy in selected indications where radiotherapy is used as standard of care but fails due to radio-resistance. After its first clinical validation, the systemic administration of Dbait will expand its scope to all indications currently treated by radiotherapy and chemotherapy. The ability of siDNA to improve therapeutic efficacy without additional cytotoxicity has potential to extend the market for radiotherapy and chemotherapy. It is anticipated that DNA Therapeutics will have a pipeline with products at different stages of development within the next 5 years, throughout balanced proprietary and partnered programs, thus achieving rapidly significant value creation and providing the exit opportunity for its initial investors.

About SGAM SEFTI

SGAM SEFTI (Specialized European fund for Therapeutic Innovation) is a venture fund dedicated to investments in unlisted French and European companies operating principally in the pharmaceutical field and in medico-surgical applications. The fund acquires interests in the firms which it accompanied through the set-up stage in order to develop and increase the value of innovative therapeutic projects coming mainly from academic research in France, Switzerland and Italy. SGAM SEFTI investment is focused in target companies at an initial stage of development and which have further development opportunities with the potential to provide a capital gain in the medium term through licensing and sale.

    Contacts:

    DNA Therapeutics
    Prof. Jian-Sheng Sun, Ph.D.
    Chairman and CEO
    Phone: +33-624-753-239
    Email: sun@dna-therapeutics.com

    SGAM SEFTI
    Dr. Beatrice Denys, M.D., MBA
    Manager of the fund
    Phone: +33-156-378-712
    Email: Beatrice.denys@sgam.com


'/>"/>
SOURCE DNA Therapeutics SA
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
2. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
3. Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials
4. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
5. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
6. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
7. Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic in Acute Post-Operative Pain
8. ExonHit Therapeutics Expands Strategic Collaboration With Allergan
9. Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults
10. Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis
11. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, Inc., ... development and manufacturing of collagen and mineral based ... today that Bill Messer has joined ... to further leverage the growing portfolio of oral ... Bill joins the Collagen Matrix executive ...
(Date:6/24/2016)... , June 24, 2016   Bay ... Rehabilitation Network,s Dean Center for Tick Borne ... Medicine and Rehabilitation, MIT Hacking Medicine, University of ... Innovation, today announced the five finalists of ... Lyme disease.  More than 100 scientists, clinicians, researchers, ...
(Date:6/24/2016)... June 24, 2016 Research ... "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural Health ... Structural electronics involves electronic and/or electrical ... structures, replacing dumb structures such as vehicle bodies ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is underway. ... transport experience for the millions of people who require these medical transport services ... industry through the use of technology. Now, SmartEMS has put forth an industry-changing ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
Breaking Medicine News(10 mins):